• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Actinium Pharmaceuticals Inc (NY: ATNM )

    7.310 -0.240 (-3.18%)
    Official Closing Price Updated: 8:00 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 418,917
    Open 7.570
    Bid (Size) 7.310 (5)
    Ask (Size) 8.000 (6)
    Prev. Close 7.550
    Today's Range 7.310 - 7.700
    52wk Range 4.000 - 10.24
    Shares Outstanding 21,331,314
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
    Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
    Via Newsfile
    Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
    Via AB Newswire

    Performance

    YTD
    +37.41%
    +37.41%
    1 Month
    -15.59%
    -15.59%
    3 Month
    -20.54%
    -20.54%
    6 Month
    +37.66%
    +37.66%
    1 Year
    -9.42%
    -9.42%

    More News

    Read More
    Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
    Via FinancialNewsMedia
    Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
    From FN Media Group LLC
    Via GlobeNewswire
    Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
    Via FinancialNewsMedia
    Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
    Via Newsfile
    Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
    Via FinancialNewsMedia
    Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
    Via InvestorPlace
    Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
    Via InvestorPlace
    3 Cheap Biotech Stocks to Buy Now: May 2024
    Via InvestorPlace
    Exposures Product Safety
    Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
    Via AB Newswire
    Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
    Via AB Newswire
    ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
    Via Investor's Business Daily
    Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
    Via AB Newswire
    Topics Economy
    Exposures Interest Rates
    Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
    Via AB Newswire
    Topics Economy
    Exposures Interest Rates
    Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
    Via AB Newswire
    Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
    Via InvestorPlace
    Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
    Via AB Newswire
    Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
    Via AB Newswire
    Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.